Candidiasis Therapeutics Market Size, Share, Report and Forecast 2024-2033

The Business Research Company has updated its global market reports, featuring the latest data for 2024 and projections up to 2033

The Business Research Company presents an extensive market research report on the Candidiasis Therapeutics Global Market Report 2024, furnishing businesses with a competitive edge through a detailed examination of the market structure, encompassing estimates for various segments and sub-segments.

Furthermore, the report highlights on emerging trends, significant drivers, challenges, and opportunities, providing all necessary data for thriving in the industry. This report market research offers a comprehensive perspective, including an in-depth analysis of the present and future scenarios within the industry.

Market Sizing:

The candidiasis therapeutics market size has grown steadily in recent years. It will grow from $3.06 billion in 2023 to $3.19 billion in 2024 at a compound annual growth rate (CAGR) of 4.4%. The growth in the historic period can be attributed to increased incidence of candidiasis, antibiotic use and resistance, hospital-acquired infections, shift in fungal resistance patterns, awareness and education programs..

The candidiasis therapeutics market size is expected to see steady growth in the next few years. It will grow to $3.66 billion in 2028 at a compound annual growth rate (CAGR) of 3.5%. The growth in the forecast period can be attributed to precision medicine approaches, global antifungal stewardship programs, increasing prevalence of candida auris, global efforts against antifungal resistance.. Major trends in the forecast period include advancements in drug delivery technologies, telemedicine and remote patient monitoring, patient-centric care, combination therapies, collaborative research initiatives..

Request for free sample report -
https://www.thebusinessresearchcompany.com/sample.aspx?id=13182&type=smp

Key Market Players:

Pfizer Inc., Biocon Limited, Torrent Pharmaceuticals Ltd., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., AbbVie Inc., Bayer AG, Novartis AG, Sanofi S.A., AstraZeneca plc., GSK plc., Amgen Inc., Teva Pharmaceutical Industries Ltd., Astellas Pharma Inc., Cipla Inc., Bruker Corporation, Lupin Limited, Galapagos NV, Basilea Pharmaceutica Ltd., WOCKHARDT Limited, Pacgen Life Science Corporation, Cidara Therapeutics Inc., Ablynx NV, Amplyx Pharmaceuticals Inc., NovaDigm Therapeutics Inc., SCYNEXIS Inc., Medivir AB, Mycovia Pharmaceuticals Inc., NovaBiotics Inc., Matinas BioPharma Holdings Inc. are prominent players in the industry.

Market Drivers:

The growing incidence of fungal infections is expected to propel the growth of the candidiasis therapeutics market going forward. Fungal infections are illnesses caused by various fungi that can affect the skin, mucous membranes, and internal organs in humans. The rising number of individuals with compromised immune systems and individuals with fungal infections increases the susceptibility to candidiasis, creating opportunities for manufacturers to develop and supply specialized and more effective antifungal drugs that target the underlying fungal pathogens, relieve symptoms, prevent complications, promote patient recovery, reduce the spread of Candida infections within healthcare facilities, and contribute to better patient outcomes. For instance, in July 2023, according to the Centers for Disease Control and Prevention (CDC), a US-based public health agency, fungal infection-related hospitalizations reached a total of 59,212 by 2021, with the rate of these hospitalizations increasing from 25.0 in 2020 to 26.8 in 2021 per 10,000 hospitalizations, with an average annual increase of 8.5%. Moreover, the fungal hospitalizations with the highest death rates among COVID-19 patients were linked to aspergillosis (57.6%), invasive candidiasis (55.4%), mucormycosis (44.7%), and unspecified mycoses (59.0%). Therefore, the growing incidence of fungal infections will drive the growth of the candidiasis therapeutics market.

Market Segments Include:
1) By Treatment Type: Medication, Surgery, Other Treatments
2) By Anatomy Type: Oral Candidiasis, Vulvovaginal Candidiasis, Cutaneous Candidiasis, Invasive Candidiasis, Systemic Candidiasis
3) By Mode of Administration: Injectable, Oral, Other Mode of Administrations
4) By Patient Population: Adults, Pediatrics
5) By End User: Hospitals, Homecare, Specialty Clinics, Other End Users

The report answers the following questions:
What are the primary factors propelling the market during the projected period?

In which region is the most substantial growth expected?

Which trend will take center stage in the upcoming period?

Learn More About The Market Report -
https://www.thebusinessresearchcompany.com/report/candidiasis-therapeutics-global-market-report

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Want To Know More About The Business Research Company?

The Business Research Company (www.thebusinessresearchcompany.com) is a market intelligence firm that pioneers in company, market, and consumer research. Located globally, TBRC's consultants specialise in various industries including manufacturing, healthcare, financial services, chemicals, and technology.

Global Market Model - World's Most Comprehensive Database

The Business Research Company's flagship product, Global Market Model (www.thebusinessresearchcompany.com/global-market-model) is a market intelligence platform covering various macroeconomic indicators and metrics across 60 geographies and 27 industries. The Global Market Model covers multi-layered datasets which help its users assess supply-demand gaps

This release was published on openPR.